Takayasu arteritis (TA or TAK) is a chronic large vessel vasculitis with predilection to affect the aorta and its branches. The new 2022 ACR/EULAR classification criteria for Takayasu arteritis incorporated imaging characteristics as an absolute requirement. ESR and CRP fails in accuracy as disease activity markers. Pentraxin 3 appears to be a relatively superior biomarker, which correlates with ITAS 2010 as per several studies. PET-CT is also increasingly being studied for assessing disease activity with variable results. The management of TAK involves use of steroids with upfront steroid sparing immunosuppressive agents. MMF is one such conventional DMARD/immunosuppressant with good efficacy and better safety profile, as reported in various cohort studies. Tocilizumab is proved to be a rapid remission inducing agent in refractory Takayasu arteritis in observational studies. TNF inhibitors in many uncontrolled studies showed good responses, and there is a need for good RCTs for confirmation. JAK inhibitors have also been used with success in a few reports.
Keyphrases
- disease activity
- rheumatoid arthritis
- rheumatoid arthritis patients
- pet ct
- systemic lupus erythematosus
- juvenile idiopathic arthritis
- ankylosing spondylitis
- machine learning
- high resolution
- positron emission tomography
- case control
- pulmonary artery
- aortic valve
- mass spectrometry
- pulmonary hypertension
- fluorescence imaging
- pulmonary arterial hypertension
- coronary artery
- loop mediated isothermal amplification